A Phase 2 Double-blind Randomized Placebo-controlled Multicenter Study to Evaluate Efficacy Safety and Tolerability of JBT-101 in Systemic Lupus Erythematosus

Brief description of study

This research study is being done to test the effect, safety, and tolerability of the experimental drug JBT-101 in subjects with Systemic Lupus Erythematosus (SLE). The study will examine whether JBT-101 stops inflammation and how well JBT-101 is tolerated. The study will evaluate whether JBT-101 will decrease the pain associated with active arthritis or tendonitis in Systemic Lupus Erythematosus (SLE) subjects. JBT-101 is an experimental drug being tested in subjects with SLE in this study. Corbus Pharmaceuticals, Inc. will supply this study drug. JBT-101 is manufactured entirely from chemicals and its structure is similar to the end product of a chemical in marijuana. This drug was designed to have the known anti-inflammatory properties of marijuana without the effects on brain function and mood. The drug will not have the "high feeling " of marijuana. The FDA has not approved JBT-101 for any disease


Clinical Study Identifier: s17-00084
ClinicalTrials.gov Identifier: NCT02465437
Principal Investigator: Amit Saxena.
Other Investigator: Janine M. Sullivan.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.